GlassScriptPhysician profile
Katie Hymel
NPI 1437710522
$2,740.83
in general payments reported to CMS, 2019-2025
26 companies · $1,124 in 2025
The $1,124 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3.96 · 2022: $297 · 2023: $853 · 2024: $463 · 2025: $1,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,370 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,370.24 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $719.83 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $231.00 | 2022-2023 | |
| Glaxosmithkline, LLC. | $176.94 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $168.27 | 2023-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $160.32 | 2023-2025 | Veozah |
| Axsome Therapeutics, INC. | $153.31 | 2025 | Auvelity |
| Lilly USA, LLC | $126.30 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $121.25 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $99.18 | 2022-2023 | Austedo Xr, Ajovy |
| Merck Sharp & Dohme LLC | $87.24 | 2022-2023 | Belsomra, Verquvo, Steglatro |
| Ardelyx, INC. | $85.02 | 2024-2025 | Ibsrela |
| Dexcom, INC. | $72.94 | 2024-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $69.68 | 2023 | |
| Novartis Pharmaceuticals Corporation | $62.68 | 2023-2024 | |
| Lundbeck LLC | $59.14 | 2025 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.75 | 2025 | Caplyta |
| Vertex Pharmaceuticals Incorporated | $54.13 | 2025 | |
| Exact Sciences Corporation | $51.98 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $46.08 | 2023-2025 | Ozempic, Rybelsus |
| Vanda Pharmaceuticals INC. | $36.27 | 2025 | Fanapt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.79 | 2023-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $21.09 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.33 | 2023 | |
| Genzyme Corporation | $17.26 | 2025 | |
| Janssen Pharmaceuticals, INC | $12.09 | 2022 | |
| Genentech USA, INC. | $3.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Hymel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.